The Kidney Dynamics Study
Currently Recruiting
8 Sep 2026
$4,100 - $4,350
Melbourne, Australia
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney failure. It is a genetic condition which causes cysts to develop in the kidneys and can eventually lead to kidney failure.
Currently, there is only one approved treatment for ADPKD. While this treatment can be effective at slowing the disease down, it can cause serious side effects relating to the liver.
The study drug, RT‑312 has been designed to avoid these harmful side effects in the liver, providing a potentially safer medication to those living with ADPKD.
Join our clinical trial
This is a first-in-human (FIH) study, meaning it is the first time the potential treatment is being tested in people. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee. It is not known whether the study drug may cause unexpected, serious, or life-threatening side effects. While these are considered unlikely, you will be carefully monitored throughout the study and provided with prompt treatment if any such effects occur.
Before joining, you’ll receive detailed information about the study, meet with a doctor, and have the chance to ask any questions.
What to expect
- Participation in a monitored clinical environment
- Study visits scheduled
- Support from a professional medical team
- Reimbursement for your time and commitment
Study schedule
| Intake 1 | In-clinic stay:
Stay 1: 8 September 2026 – 11 September 2026 Stay 2: 5 October 2026- 8 October 2026 |
Follow-up visits:
16 September 2026
13 October 2026
|
| Intake 2 | In-clinic stay:
Stay 1: 9 September 2026 – 12 September 2026 Stay 2: 6 October 2026- 9 October 2026 |
Follow-up visits:
17 September 2026
14 October 2026
|
Study dates are subject to change. Our team will confirm details with you during the screening process.
Trial details
Study duration
- 6 night stay, split into 2 x 3 night stays
- 2 follow-up visits
Study medication
The study drug will be administered as a tablet
Additional eligibility
• Weight between 50-120kg (inclusive)
• No significant medical history
• Non-smokers or smoking 2 cigarettes per day or 10 cigarettes per week
• Willing to abstain from smoking during inpatient stay
Ethics
An independent ethics committee has approved this clinical trial.
Are you a match?
Age
18 - 45 years old
Remuneration
$4,100 - $4,350 *with screening reimbursement.
Full details outlined in consent form.
Gender
Male, Female or Female of non-childbearing potential
BMI
BMI 18 - 32 kg/m2
Commitment
6 nights, 2 clinic visits
Medical condition
Not taking any medications